869640-41-5

Usage

Uses

Used in Pharmaceutical Industry:
5,6,7,8-tetrahydro-7-(phenylmethyl)-1,7-naphthyridin-2(1H)-one is used as a potential drug candidate for the development of therapeutic agents targeting neurological disorders. Its unique structure allows for specific interactions with biological targets, offering a new avenue for the treatment of various neurological conditions.
5,6,7,8-tetrahydro-7-(phenylmethyl)-1,7-naphthyridin-2(1H)-one is also used as a potential drug candidate for the development of anti-inflammatory agents. Its ability to modulate inflammatory pathways and reduce inflammation makes it a promising compound for the treatment of inflammatory diseases.
In addition to its direct therapeutic applications, 5,6,7,8-tetrahydro-7-(phenylmethyl)-1,7-naphthyridin-2(1H)-one may also be utilized in drug delivery systems to enhance the bioavailability and efficacy of other pharmaceutical compounds. Its unique structure and functional groups can be leveraged to improve the delivery of drugs to target tissues, potentially increasing the therapeutic outcomes for various conditions.

Upstream product

• 239137-39-4 3-amino-4-bromopyridine 
• 1452560-16-5 ethyl (E)-3-(3-amino-4-pyridyl)prop-2-enoate 
• 54920-82-0 1,7-naphthyridine-2(1H)-one 
• 105752-11-2 4-iodopyridin-3-amine 
• 100-39-0 benzyl bromide 

Downstream Products

• 869640-42-6 7-benzyl-2-(3-pyrrolidin-1-ylpropoxy)-5,6,7,8-tetrahydro-1,7-naphthyridine 

Relevant academic research and scientific papers

1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D] PYRIMIDIN -3 - ONE ANALOGS

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

NRF2 ACTIVATOR

Provided are tetrahydroisoquinoline derivatives as Nrf2 activators.

NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The present invention provides novel compounds having the general formula (I): wherein R1, R 2, R 3, U, V, W, X and Y are as described herein, compositions including the compounds and methods of using the compounds.

QUINOLINE DERIVATIVE

This compound represented by general formula (I) and having a quinoline skeleton has a strong Axl inhibitory activity. Consequently, this compound can be a therapeutic agent for Axl-related diseases, for example, cancers such as acute myeloid leukemia, chronic myeloid leukemia, melanoma, breast cancer, pancreatic cancer and glioma, kidney diseases, immune system diseases and cardiovascular diseases.

PYRROLO PYRIMIDINE DERIVATIVE

The compound represented by general formula (I) has strong Axl inhibition activity by means of a pyridone ring structure being introduced into a pyrrolo pyrimidine skeleton, and so the result can serve as a treatment agent for Axl-related diseases, for example cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors, renal disease, immune system disorders, and cardiovascular disease.

Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands

The invention relates to tetrahydronaphthyridine derivatives having formula (I) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said tetrahydronaphthyridine derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.